The Cooper Companies, Inc. Current$54.14
Target$63.36
Return+17.0%
Sep 15, 2026
CooperCompanies offers a discounted entry into durable contact-lens and fertility franchises with strong cash flow and buybacks, but it must normalize U.S. channels and rebuild credibility after the Q3 guidance reset and failed CooperSurgical sale.
Sep 14, 2026
MiniMed has a credible diabetes-technology growth engine led by Flex, CGM attachment and a strong pipeline, but negative free cash flow, low current returns and an expensive forward multiple make the post-spin risk-reward unattractive today.
Agilent Technologies, Inc. Current$157.93
Target$172.64
Return+9.3%
Aug 29, 2026
Agilent is a high-quality, cash-generative tollbooth in life sciences and analytical instruments with rapid margin expansion, though investors must accept a steep valuation premium amid cyclical biotech capex headwinds and China trade risk.